JPMorgan Chase & Co. Reiterates “Neutral” Rating for Merck KGaA (MRK)

JPMorgan Chase & Co. restated their neutral rating on shares of Merck KGaA (FRA:MRK) in a research note published on Wednesday, January 17th.

Other equities research analysts also recently issued reports about the stock. Oddo Bhf set a €125.00 ($154.32) price target on shares of Merck KGaA and gave the company a buy rating in a research note on Friday, November 10th. Citigroup set a €123.00 ($151.85) price objective on shares of Merck KGaA and gave the company a buy rating in a report on Monday, September 25th. UBS Group set a €120.00 ($148.15) price objective on shares of Merck KGaA and gave the company a buy rating in a report on Monday, January 8th. Goldman Sachs Group set a €105.00 ($129.63) price objective on shares of Merck KGaA and gave the company a neutral rating in a report on Tuesday, September 19th. Finally, Kepler Capital Markets set a €119.00 ($146.91) price objective on shares of Merck KGaA and gave the company a buy rating in a report on Thursday, September 21st. Twelve investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of €107.57 ($132.80).

Shares of Merck KGaA (FRA:MRK) traded down €1.08 ($1.33) during trading on Wednesday, reaching €81.10 ($100.12). 780,966 shares of the company’s stock were exchanged. The firm has a market capitalization of $10,430.00 and a P/E ratio of 18.99. Merck KGaA has a 12-month low of €80.50 ($99.38) and a 12-month high of €115.00 ($141.98).

COPYRIGHT VIOLATION WARNING: “JPMorgan Chase & Co. Reiterates “Neutral” Rating for Merck KGaA (MRK)” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://ledgergazette.com/2018/02/11/jpmorgan-chase-co-reaffirms-neutral-rating-for-merck-kgaa-mrk.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply